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SUMMARY
To assess the socio-economic impact of infectious intestinal disease (IID) on the health care sector,
cases and their families, cases of IID ascertained from a population cohort component and those
presenting to general practices were sent a socio-economic questionnaire 3 weeks after the acute
episode. The impact of the illness was measured and the resources used were identiﬁed and costed.
The duration, severity and costs of illness linked to viruses were less than those linked to bacteria.
The average cost per case of IID presenting to the GP was £253 and the costs of those not seeing
a GP were £34. The average cost per case was £606 for a case with salmonella, £315 for
campylobacter, £164 for rotavirus and £176 for SRSV. The estimated cost of IID in England
was £743m expressed in 1994/5 prices. The costs of IID are considerable and the duration of the
illness was found to be longer than previous reports have suggested.
INTRODUCTION
This study is the ﬁrst prospective assessment of the
impact and costs of all infectious intestinal diseases
(IID) occurring in the community. Many infections
are unreported. These undetected cases, though likely
to be less severe, are numerous [1]. This study includes
such cases. Studies undertaken in the United States,
use a modelling approach to calculate the costs of in-
fectious foodborne disease based on estimated inci-
dence rates [2]. This study provides a prospective
assessment of cases including those who do not seek
medical intervention and delineates costs to the health
sector and to cases and their families.
This study arose in response to the interest in econ-
omic implications of IID following the Richmond
Committee [3] inquiries that reported costs based on
studies of salmonellosis [1, 4]. Data collection was con-
ducted between August 1993 and January 1995, analy-
sis took place during 1996–8 and the report of the study
was published in December 2000 [5].
AIMS AND METHODS
The aim of the socio-economic component of the IID
study was to estimate the impact of the illness on cases* Author for correspondence.
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and to identify and cost the resources used. Cases of
IID were ascertained from three components : a case
control component of patients registered with 34 gen-
eral practices; and a population cohort component
consisting of a sample of selected subjects, from
patients’ lists in 70 practices, who were sent a risk
questionnaire and asked for stool specimens; and an
enumeration component of cases from 36 general
practices who received routine investigations only.
Details of the study design, case deﬁnition and testing
of stool specimens are presented elsewhere [5–7]. Ethi-
cal approval to conduct the inquiry was obtained.
Organism-speciﬁc incidence rates were based on
data from the case control and population cohort
components, as stools of cases in the enumeration
study were not tested by the study. The population co-
hort was also used to estimate the consulting pat-
terns of those who developed IID in the community.
In theGP case-control component study and the popu-
lation cohort component stool specimens were part
of the study design. The costs of these were study costs
not costs of illness and were thus not included in the
cost analysis. The enumeration component was used
to assess the normal practice of sending specimens for
testing. Details of the methods are provided elsewhere
[5, 7, 8]. A socio-economic questionnaire was sent to
all cases 3 weeks after the start of the acute episode.
Data on age, sex and social class, from the risk factor
questionnaire, and the laboratory results were linked
to the socio-economic questionnaire data. The results
of the socio-economic analysis are reported here for
all cases in the GP case-control component and those
in the population cohort component. For details of
the enumeration component consult the full report [5].
The cases in the population component are analysed
in two groups, those who saw a GP and those that
did not. The analysis includes all cases of IID and is
provided by organisms where there were suﬃcient
numbers for robust cost estimates to be derived: all
salmonellas and S. enteritidis ; all campylobacters and
C. jejuni ; enterovirulent E. coli and enteroaggregat-
ive E. coli (EAggEC); rotavirus and rotavirus group
A, Clostridium diﬃcile, and small round structured
virus (SRSV) [7].
The impact of the illness on the activities of daily
living were measured on a scale that began with a hos-
pital admission, where the case was conﬁned to bed,
and followed an ordering from most severe to least
severe, i.e. from hospitalization to full participation
in all normal activities in the home and outside. The
use of National Health Service (NHS) resources was
identiﬁed from the questionnaires. Costs estimates
were based on vectors of costs for items of service, e.g.
a GP visit, a day spent in hospital or a test sample. The
costs of hospital in-patient stay, Accident and Emerg-
ency Department (A&E) visits and out-patient visits
were estimated based on Chartered Institute of Public
Financial Accountants’ health data [9] for hospitals
having characteristics of those admitting cases of
acute infections. Costs of using GP and community
services were estimated using data from the Personal
Social Services Research Unit data base [10]. As cases
were studied over 2.5 years. The costs were aggre-
gated and mid-point estimates were used. Prescription
charges were used as a guide to prescription costs
as it was not possible to estimate ingredient costs or
administration costs precisely as the details of drugs,
dose or length of treatment were not reported. As an
additional check on this method a small sample of
doctors was asked to describe the normal treatment
that they would oﬀer for intestinal infectious disease.
These responses elicited treatment regimes that varied
in price from less than £2 to more than £12.50.
Weights for the likelihood of prescribing each item
were not available but in so far as the professionals
were able to comment they considered that the nor-
mal treatment would have been at the lower end of
the distribution. Given this uncertainty the prescrip-
tion charge was used as a surrogate for costs of the
prescribed drugs. These costs can be adaptedwhen new
material becomes available. Prescription payments
from those who were not exempt were deducted from
NHS costs and added to patients’ costs. Costs of lab-
oratory tests were estimated from a survey of par-
ticipating laboratories and interpreted in the light of
the Audit Commission report [11]. Estimates of direct
out-of-pocket expenses were provided by cases re-
sponding to the questionnaire who were asked the
cost of items purchased because of the illness. Costs
to persons who accompanied cases to GP surgeries
and hospitals and those staying with children in hos-
pitals were also collected. Time oﬀ work was esti-
mated from reported absences and valued using the
New Earnings Survey for 1995 [12]. Information on
the age of those caring for and accompanying cases
was not collected. The estimates of time oﬀ work
were adjusted for gender and occupational grouping,
these were the main determinants of wage diﬀerences.
Statistical analysis of a study where two vectors, in
this case numbers and costs, are combined presents
a problem for estimations of the relevant conﬁdence
intervals. For this reason conﬁdence intervals have
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been provided for the estimated number of events.
Geometric means are given to report the number of
events as the data is highly skewed but arithmetic
means were used to estimate costs. A sensitivity analy-
sis was applied to the costs, assuming the vectors were
increased or decreased by 10, 20 and 50%, to indicate
the likely boundaries of costs. The robustness of the
estimates was considered in this context.
RESULTS
A total of 4389 cases completed the socio-economic
questionnaire. The response rate from the study popu-
lation was 41% (1652/4026 cases) in the GP case-
control component, 80% (555/675 cases) in the popu-
lation cohort component, and 46% (2182/4744 cases)
in the enumeration component. Sixty-three percent in
the GP case-control component and 82% of those
in the population cohort component returned both a
risk questionnaire and a socio-economic question-
naire. The cases returning the socio-economic ques-
tionnaire were not signiﬁcantly diﬀerent to those in
the other components in respect of age, sex, and social
class [6].
Characteristics of the cases
A total of 373 (8.5%) were under 1 year old, 859
(19.6%) were under 5; 459 (10.5%) were over 5 and
under 16 years old; 1888 (43%) were adults under 60
years of age and 673 (15.3%) adults over 60 years of
age. Age was missing for 137 cases. There were more
male children under 16, (47% males and 37% fe-
males), but more female adults (49%) than males
(38%).
The case reported was the only person aﬀected in
over 80% of households if the case was an adult but in
only 60% of households if the case was a child. The
other person in the home most likely person to be ill,
if the case was a child, was the mother and if the case
was an adult it was the partner of the case.
Characteristics of the illness – activities of daily living
The impact of the illness for each study component
for those who did and those who did not consult a
GP is shown in Figure 1. Proportionately fewer cases
were admitted to hospital from the GP case-control
component than those from the population cohort
cases who saw a GP (1.8 and 4%, respectively,
P=0.063). Most adults between 16–60 years of age
70
60
50
40
30
20
10
0
GPcc study Pop. cohort study Saw GP Did not see GP
Study
Pe
rc
en
ta
ge
 o
f 
ca
se
s
Hospital confined to bed
Hospital able to get up
Home confined to bed
Home up but not able to do normal activities
Home but able to do normal activities
Feeling ill but able to go to the shops
Source: Socio-economic survey
Fig. 1. The impact of illness : percentage of cases reporting spending time in the diﬀerent stages, by study.
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reported spending time in bed at home because of
illness. A total of 38% of cases in the GP case-control
component reported being ‘conﬁned to bed’ for 3 days
and 25% of cases in the population cohort component
for nearly 2 days on average. The most frequently re-
ported stages were ‘at home but not able to do normal
activities ’ and ‘at home able to undertake normal
activities ’. In the GP case-control component 67 and
53% of cases reported being in these stages for 4.5
days on average. In the population cohort component
47 and 50% of cases reported being in these stages for
2.5 days on average. In the GP case-control compon-
ent 54% of cases with salmonella and 52% of cases
with campylobacter reported being at home ‘conﬁned
to bed’ for 4 days and 3.5 days, respectively. Seventy-
six percent of cases with these infections reported
being at home ‘not able to do normal activities ’ for an
average of 4.5 days.
In the GP case-control component 30% of all IID
cases reported losing 6 days from education while
54% of cases with salmonella reported losing 4.5 days.
Children reporting time oﬀ school reported an aver-
age of 4 days and adults, 16 years of age and over, lost
an average of 7 days education. In the population
cohort component those who saw a GP lost 4 days
and those who did not, 2 days.
In the GP case-control component 42% of all
adult cases with IID reported losing time oﬀ work.
This group lost an average of 6 days paid employment
(range 1–80 days). Cases with salmonella reported
9 days oﬀ work on average (of which those with
S. enteritidis reported 7 days), campylobacter 6 days,
enterovirulent E. coli 5 days, rotavirus 4 days and
SRSV 3 days. In the population cohort component
only 20% of adults reported time oﬀ work, those who
had seen a GP reported an average of 3 days whilst
those who had not 2 days.
In the GP case-control component about 5% of
cases reported exclusion from school or work because
of the risk of their spreading infection. These cases
were away for an average of 6 days. In the population
cohort component 3% were excluded from work or
school for an average of 2 days.
In the GP case-control component 26% men and
49%women reported not being able to undertake nor-
mal household duties. These cases reported being un-
able to do normal activities for 5 days on average.
Fifty percent of salmonella cases reported an average
of 7 days, 39% ofClostridium diﬃcile and SRSV cases
reported 3 days. In the population cohort component
25% of cases reported an average of 2 days.
In the GP case-control component study 724 cases
(44%) reported an average of 8 days lost leisure. Cases
with salmonella or EAggEC reported an average of 10
days and rotavirus and SRSV cases 7 and 5 days, re-
spectively. In the population cohort component 36%
of those who had seen a GP reported 6 days and 34%
of those who did not reported 3 days lost leisure.
Use and costs of resources to the NHS
Costs are reported as average costs for all IID cases in
the component unless otherwise speciﬁed (Tables 1, 2).
Hospital care
A total of 29 cases (1.8%) in the GP case-control
component were in hospital for 4 days on average.
Of these ﬁve children (3.5%) under 1 year of age were
hospitalized. In the GP case-control component the
cost of hospitalization was £15.66 per IID case. Six
cases, (4%) of those who saw a GP, in the population
cohort component were hospitalized. The average cost
per IID case was £13.18 for those who had seen a GP.
Twenty-three cases (1.4%) in the GP case-control
component visited A&E. All those under 1 year of age
and those over 60 in the GP case-control component
study who visited A&E were admitted to hospital.
Six cases (1.1%) in the population cohort component
visited A&E, four were admitted. All had seen a GP.
In the GP case-control component 20 cases (1.2%)
attended out-patients’ on 37 occasions. In the popu-
lation cohort component 7 cases visited out-patients’
on 20 occasions (4.6% of cases seeing a GP).
General practice care
Consultations with GPs took place in the surgery, in
the patients’ homes and by telephone. All cases in the
GP case-control component should, according to the
study design, have consulted a GP. In the population
cohort component 149 (27%) cases reported consult-
ing a GP.
In the GP case-control component 457 cases (22%)
were visited at home. The average cost was £13.59 per
case. Eighty-ﬁve cases (40%) of those over 60 years of
age had home visits. Salmonella cases had the highest
cost for GP consultations per case followed by rota-
virus cases. In the population cohort component 7%
of cases had a GP consultation at home.
In the GP case-control component 87% of cases
visited the surgery, 24% made more than one visit.
The average cost for those visiting the surgery was
4 J. A. Roberts and others
£20.45 per IID case (see Table 1). The children under
1 year of age had the highest proportion of multiple
visits, 35% made two or more visits. Surgery visits
were highest for cases with C. diﬃcile, £23.61 per case
(Table 2). In the population cohort component 80%
of cases consulting a GP did so at the surgery; 59%
visited once. The average cost of visiting the GP at the
surgery in this component was £4.96. Most visits were
made either by adults under 60 years old or children
under 1 year old. In each study component up to 29%
of cases telephoned the GP and 2.5% of cases were
visited by a nurse.
Investigations
In the enumeration component 33% of cases return-
ing the socio-economic questionnaire had a stool test.
This rate was used to estimate costs of routine tests in
theGP case-control component andpopulation cohort
component studies. Four percent of cases reported
having had a blood test, 6% of cases reported
having had a urine test.
Treatments
The proportion of cases receiving a prescription was
similar in each study component (41–44%) and aver-
aged 1.4 prescriptions per case.
Total NHS
The total cost per case to the NHS was £62.41 for
cases in the GP case-control component and in the
population cohort component £28.64 for all cases in
the cohort and £107.14 per case for cases visiting a GP
(see Table 1). The highest cost per case to the NHS
by organism was £131.79 for salmonella cases in the
GP case-control component (Table 2). Hospital costs
represented 30% of the total NHS costs and the
highest were for those with salmonella (Table 2).
Table 1. Average cost per case to the NHS by category of cost and study
Cost category
GP case-control
component
(n=1652)
Population
cohort
component –
those who saw
a GP (n=149)
Population cohort
component – total
(n=555)
Primary care costs
GP home visit 13.59 16.72 4.49
GP surgery visit 20.45 18.48 4.96
Transport to GP 0.95 0 0
Phone GP 0.98 0.77 0.21
Nurse home visit 0.61 0.24 0.06
Prescriptions 2.19 2.69 0.72
Total 38.77 38.9 10.44
Percentage 62.12 36.31 36.45
Laboratory costs
Stool test 5.30 5.30 1.42
Blood test 0.18 0.22 0.06
Urine test 0.58 1.20 0.15
Specimen collection 0.02 .02 0.02
Specimen postage 0.01 .01 0.01
Total 6.09 6.75 1.66
Percentage 9.76 6.30 5.8
Hospital costs
Hospital admission 15.66 49.00 13.18
A&E visit 0.49 1.09 0.29
OPD visit 1.01 6.30 1.70
Transport to hospital 0.39 5.10 1.37
Total 17.55 61.49 16.54
Percentage 28.12 57.39 57.75
Total 62.41 107.14 28.64
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Table 2. Average cost per case to the NHS by category of cost and organism GP case-control component
No. IID
organism
(n=663)
Salmonella
sp.
(n=90)
S. enteritidis
(n=59)
Campylobacter
sp.
(n=192)
C. jejuni
(n=172)
E. coli
(n=197)
Enteroaggregative
E. coli
(n=65)
C. diﬃcile
(n=18)
Rotavirus
(n=122)
Rotavirus Gp3
(n=119)
SBSV
(n=83)
Primary care costs
GP surgery visit 18.72 21.53 19.31 19.39 19.27 21.83 21.97 23.61 20.34 20.57 16.80
GP home visit 11.56 21.41 24.69 16.16 16.12 8.59 10.12 10.44 20.03 20.14 13.02
Transport to GP 0.79 0 0 0.78 0.87 0.38 0 4.17 0.61 0.63 0
Phone GP 0.74 1.59 1.69 1.29 1.23 0.71 0.71 1.13 1.67 1.69 0.80
Nurse home visit 0.51 0.93 1.02 0.69 0.77 0.67 0.18 0 0.89 0.91 0.29
Prescriptions 1.78 1.70 0.94 2.10 1.85 3.15 2.56 1.68 2.80 2.63 2.13
Laboratory costs
Blood test 0.17 0.20 0 0.07 0.08 0.14 0.23 0.11 0 0 0.05
Urine test 0.77 0.40 0.46 0.09 0.05 0.32 0.28 0 0.37 0.38 0.33
Specimen
collection
0.02 0.07 0 0.03 0.03 0.02 0 0.11 0 0 0.01
Hospital costs
Hospital
admission
15.95 81.25 0 8.79 5.89 15.99 0 0 0 0 2.71
A&E visit 0.41 0.60 0 0.28 0.31 0.55 0.83 0 0 0 0.33
OPD visit 1.63 0 0 0.23 0 0.69 0 0 0 0 0.54
Transport to hospital 0.24 2.11 0 0 0 0.48 0 0 0 0 0
Total 53.29 131.79 48.10 49.90 46.47 53.52 36.89 41.14 46.71 46.95 36.99
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Resource use and direct costs to cases and carers
Average direct expenses to cases were £15.42 per case
in the GP case-control component and £13.38 for
those in the population cohort component who saw a
GP (Table 3). Cases with S. enteritidis had the highest
cost per case in both the GP case-control component
and in the population cohort component: £31.89
and £12.25, respectively. SRSV cases cost £12.11 and
£6.67, respectively, similar to cases who had IID but
with no target organism identiﬁed.
The person staying with children in hospital was the
mother in 82% of cases. Those accompanying cases
to A&E and out-patients’ departments were most
likely to include other family members.
The average costs to cases of days lost employment
per case was £140 in the GP case-control component,
and £52 in the population cohort component for those
who saw a GP and £17 for those that did not (Table
4). In the GP case-control component 706 (42%) cases
reported that they were cared for at home. These
cases were looked after for an average of 8 days. In
the population cohort component 211 cases (42%) re-
ported care in the home. These cases were looked after
for an average of 4 days. In the GP case-control com-
ponent the carers’ lost work was valued as £36 per
case. In the population cohort component carers lost
work worth £29 per case for those that saw a GP
and £13 for those that did not (Table 4).
Total costs of IID
The cost per IID case was £253.78 in the GP case-
control component. In the population cohort com-
ponent the cost was estimated to be £201.69 for those
who had seen a GP and £34.31 for those who had not
(Table 4).
The NHS costs represented 25% of total costs in
theGPcase-control studyand53%ofcosts in thepopu-
lation cohort component for those who saw a GP.
Direct out-of-pocket expenses were a similar pro-
portion of costs in each study component; the absol-
ute costs were highest for salmonella and lowest for
SRSV.
Sensitivity test
Geometric means with 95% conﬁdence intervals are
given for numbers of visits and contacts with GPs
and home nurses, tests, prescriptions and visits to
A&E (Table 5). The conﬁdence limits for hospital
Table 3. Average direct costs (£) to cases by category of cost, by study
Population cohort component
GP case-
control
component
(n=1652)
Those who
reported
seeing a doctor
(n=149)
All those in the case
community study
(n=555)
Primary care costs
Phone GP 0.38 0.30 0.08
Prescriptions 1.29 0.98 0.26
1.67 1.28 0.34
Miscellaneous costs
In hospital 0.13 0.15 0.04
AT OPD 0.01 0.01 0.003
Accommodation in
hospital for carer
0.21 0.61 0.16
On holiday when ill 1.08 0.46 0.14
At home when ill 10.81 9.00 5.07
12.16 10.23 5.41
Transport costs
To GP 1.00 1.3 0.36
To hospital 0.48 0.53 0.14
To laboratory 0.03 0.04 0.01
1.51 1.87 0.51
Total 15.42 13.38 6.26
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admissions, out-patients and accommodation in hos-
pital were large. The largest variation was for days ill
at home and for days ill on holiday. Some variation
would be expected because of the diversity of con-
ditions, the range of severity and the small number of
cases in some categories, i.e. hospitals admissions. It
also reﬂects the skewed distribution of illness experi-
enced by cases with a small number experiencing
prolonged symptoms.
The robustness of these estimates together with the
cost vectors used allow us to consider the likely sen-
sitivity of the results. Estimated direct costs to cases
and those who looked after them were itemized in
some detail and it is considered that these are robust
estimates lying within the 10% sensitivity band. If
hospitalized cases were under-reported in the general
practice cohort component then this would make a
substantial diﬀerence to costs. Costs of lost employ-
mentmight also have been higher than those estimated
as the time costs of caring for the full period of the
illness was not included because adjustments would
have been needed for time taken on combined house-
hold activities, and these adjustments could not be
made without further studies in households.
Estimation of cost of IID in England in 1994
Using the ratios of laboratory reports to cases esti-
mated in this study and applying these to the cases in
the population cohort component and applying these
in turn to the population estimates [5, 13] enabled
some broad calculations of the total costs of IID for
England to be made. The cost of illness of the major
organisms detected and IID with no target organism
was estimated (Table 6). Assuming that the illness
experienced by reporting cases reﬂected the illness
estimated in the population cohort component during
the study period the total costs of cases of IID, was
estimated to be £742.8 million or £78.89 per case. The
NHS costs represented 36.5% of these ﬁgures. Using
an alternative assumption based on the estimated cost
for those who did not see a GP in the population
cohort component and those who saw a GP in the GP
case-control component study the estimated cost was
£676.9m.
DISCUSSION
The burden of the illness is predominantly felt in the
community but the few cases admitted to hospital
represented 58% of the NHS costs in the population
cohort cases who had seen a GP and 28% in the GP
case control study. Cases with IID use resources that
could be used for other patients. The costs are, thus,
likely to reﬂect the opportunity costs of use of scarce
hospital resources andGP time.The avoidance of these
costs may not result in substantial ﬁnancial savings
in the short term but investment to reduce the inci-
dence of the illness may show savings in the long term
if cost-eﬀective prevention strategies can be devel-
oped.
In the cases that consulted GPs reported more
severe symptoms than those who did not, their illness
lasted longer and they incurred more NHS and per-
sonal costs. The low costs of those who do not see
Table 4. Summary of average total cost per case by category of cost and study
GP case-control
component
(n=1652)
Population cohort component –
those who saw a GP
(n=149)
Population cohort component –
those who did not see a GP
(n=406)
Cost category £ % £ % £ %
NHS costs
Primary care 38.77 15.2 38.90 19.3 0
Hospital 17.55 7.0 61.49 30.5 0
Laboratory 6.09 2.4 6.75 3.3 0
Direct costs to cases and
families
15.42 6.0 12.77 6.3 3.72 10.8
Employment costs
Cases 139.97 55.2 52.82 26.2 17.21 50.2
Carers 35.98 14.2 28.96 14.4 13.38 39.0
Total 253.78 201.69 34.31
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a GP are striking and do not reﬂect the normal under-
standing of these cases gathered from outbreak studies
[14]. Lower costs might also be expected because the
IID cases in this study include viruses whilst those
reported in other studies were associated with bac-
teria. Illness due to all serotypes of salmonella ap-
peared to last longer and be more severe than illness
due to S. enteritidis. This is compatible with other
studies [14–16].
The costs of IID captured in this study are likely to
be an underestimation as no estimate has been made
of the impact of IID in institutions, e.g. hospitals,
prisons. Also some rare organisms, that are likely to be
more expensive to treat, were not found in suﬃcient
Table 5. Geometric means and 95% conﬁdence intervals for resources used by study
GP case-control components Population cohort component study
n=1652
Geometric
mean
95% conﬁdence
interval n=555
Geometric
mean
95% conﬁdence
interval
Items which contribute
to NHS costs
no. no.
GP home visits 352 1.19 0.58–2.43 41 1.19 0.59–2.41
GP surgery visits 1329 1.27 0.55–2.91 115 1.26 0.56–2.87
Phone cells to GP 420 1.30 0.57–2.99 34 1.22 0.58–2.55
Nurse home visits 53 1.28 0.49–3.37 3 1
Blood tests 60 1.36 0.54–3.45 6 1.59 0.52–4.81
Urine tests 82 1.16 0.60–2.23 9 1
Specimen collection 26 1.20 0.56–2.55 3 1
Prescriptions 403 1.29 0.53–3.15 46 1.35 0.53–3.43
Items which contribute
to direct costs to cases
Prescriptions 267 1.30 0.54–3.11 20 1.28 0.58–2.83
A&E visit 20 1.37 0.60–3.11 5 1.15 0.63–2.11
Hospital admission 29 2.49 0.38–16.40 6 2.61 0.17–39.97
OPD visit 18 1.59 0.45–5.58 7 2.48 0.72–8.58
Accommodation of parent
in hospital
27 2.63 0.43–16.11 5 3.62 0.59–22.20
Ill on holiday 41 14.62 0.88–242.25 7 6.36 0.87–46.47
Ill at home 1194 6.24 0.34–113.23 287 3.83 0.18–82.27
Table 6. Total costs of IID in England 1994 for all IID and by organism. Estimates based on estimates of
costs from the population cohort component and GP case-control component
Organism
Estimate
(million £)
NHS costs
General
practice
NHS costs
hospitals
NHS costs
Laboratories
Direct costs to
cases and
families
Employment
costs (cases)
Employment
costs (carers)
Estimated total costs for all IID using population cohort component estimate
All IID 742.8 98.0 157.5 15.6 57.2 251.1 163.4
Estimated total cost for all IID using estimates from Population cohort component for those who did not see a
GP and estimates from the GP case-control component for those presenting to a GP
All IID 676.9 62.5 28.6 9.8 53.6 360 162.4
No target organism 318.5 24.6 13.1 0.7 27.2 174.7 78.0
Salmonella 46.4 3.6 6.4 0.05 2.7 28.2 5.4
Campylobacter 69.6 8.1 1.9 0.04 4.6 48.4 6.5
E. coli 69.3 7.7 3.9 0.1 7.3 27.1 23.2
C. diﬃcile 5.6 0.4 0 0 0.3 1.5 3.4
Rotavirus 18.2 5.1 0 0.04 1.9 2.6 8.5
SRSV 24.4 3.2 0.3 0.04 2.3 7.6 10.9
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numbers to obtain accurate estimates, e.g. E. coli
O157 [16, 17]. The estimates of hospital cost may be
underestimated, as the 1.8% of cases hospitalized in
the GP case-control component was lower than the
3.6% of cases in the enumeration component, and
4% of patients in the population cohort who saw a
GP. Some of the more severe cases may not have been
ascertained in the GP component because they were
either in hospital or too sick to participate [5, 7]. The
relationship between IID and other underlying mor-
bidities may have aﬀected the length and severity of
the illness but it has not been possible to explore these
interactions.
The study does not include a measure of the health
status of cases experiencing the illness because there are
methodological problems of applying these measures
during the acute phase of an illness. Nor are the costs
of sequelae included. No value has been placed on
loss of life attributable directly or indirectly to IID.
Nor has any value been placed on time lost from edu-
cation or leisure. The hours lost are considerable and
could be valued in extended work. The public health
costs of monitoring and investigation, apart from
the costs of some laboratory tests, have not been in-
cluded. These are often substantial in outbreaks [14].
No costs to industry other than those associated with
time away from work are included.
Comparable costs from other studies are only avail-
able for the salmonella and campylobacter cases [2].
The costs estimated appear lower than those estimated
elsewhere [1]. This diﬀerence is probably explained by
the items of costs included and by the case mix, as
this study ascertained cases in the population who
would not normally present to a GP and many of
the previous studies have estimated costs in outbreaks
that may include more severe cases and have high
public health costs [14]. Costs estimated in studies in
the United States are from models and reﬂect costs
in a diﬀerent health care system [2]. These estimates,
particularly the costs attributed to campylobacter,
are not directly comparable as they include the costs
of sequelae and values for lives lost [18, 19].
Sensitivity analysis indicates that apart from hospi-
talization and use of out-patient services the estimates
appear to be robust. Changes in the estimated distri-
bution of cases attributed to bacteria and viruses
would aﬀect aggregate costs. Duration and severity of
the illness indicated that duration and severity were
signiﬁcant variables in determining costs although the
proportion of costs explained by these variables was
low.
The study has demonstrated the severity and high
costs of the illness, adding another reason for the de-
velopment of interventions to reduce IID.
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